An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2018
Price : $35 *
At a glance
- Drugs Cepeginterferon alfa 2b (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Biocad
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.
- 12 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.